Ku GY - Search Results

1

Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.

Sihag S, Ku GY, Tan KS, Nussenzweig S, Wu A, Janjigian YY, Jones DR, Molena D. Sihag S, et al. Among authors: ku gy. J Thorac Cardiovasc Surg. 2021 Mar;161(3):836-843.e1. doi: 10.1016/j.jtcvs.2020.11.106. Epub 2020 Dec 17. J Thorac Cardiovasc Surg. 2021. PMID: 33485662 Free PMC article.

2

Esophageal cancer: adjuvant therapy.

Ku GY, Ilson DH. Ku GY, et al. Cancer J. 2007 May-Jun;13(3):162-7. doi: 10.1097/PPO.0b013e318074dbe7. Cancer J. 2007. PMID: 17620765 Review.

3

Preoperative therapy in esophageal cancer.

Ku GY, Ilson DH. Ku GY, et al. Clin Adv Hematol Oncol. 2008 May;6(5):371-9. Clin Adv Hematol Oncol. 2008. PMID: 18516027 Review.

4

Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy.

Ku GY, Goodman KA, Rusch VW, Ilson DH. Ku GY, et al. J Thorac Oncol. 2009 Mar;4(3):432-4. doi: 10.1097/JTO.0b013e3181989efa. J Thorac Oncol. 2009. PMID: 19247092 Free article.

5

Preoperative therapy for esophageal cancer.

Ku GY, Ilson DH. Ku GY, et al. Gastroenterol Clin North Am. 2009 Mar;38(1):135-52, ix. doi: 10.1016/j.gtc.2009.01.012. Gastroenterol Clin North Am. 2009. PMID: 19327572

6

Role of neoadjuvant therapy for esophageal adenocarcinoma.

Ku GY, Ilson DH. Ku GY, et al. Surg Oncol Clin N Am. 2009 Jul;18(3):533-46. doi: 10.1016/j.soc.2009.03.004. Surg Oncol Clin N Am. 2009. PMID: 19500742 Review.

7

Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Ilson DH, et al. Among authors: ku gy. Cancer. 2012 Jun 1;118(11):2820-7. doi: 10.1002/cncr.26591. Epub 2011 Oct 11. Cancer. 2012. PMID: 21990000 Free article. Clinical Trial.

8

Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.

Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH. Janjigian YY, et al. Among authors: ku gy. Am J Clin Oncol. 2014 Apr;37(2):126-30. doi: 10.1097/COC.0b013e318271b14f. Am J Clin Oncol. 2014. PMID: 23211227 Clinical Trial.

9

Adjuvant (postoperative) therapy for esophageal cancer.

Ku GY, Ilson DH. Ku GY, et al. Thorac Surg Clin. 2013 Nov;23(4):525-33. doi: 10.1016/j.thorsurg.2013.07.008. Thorac Surg Clin. 2013. PMID: 24199702 Review.

10

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS. Park DJ, et al. Among authors: ku gy. Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27. Ann Surg Oncol. 2014. PMID: 24370903

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters